The Challenges of Developing a Pediatric Ventricular Assist Device From a Fluid Dynamics Perspective

Author(s):  
Breigh N. Roszelle ◽  
Benjamin T. Cooper ◽  
Ning Yang ◽  
Steven Deutsch ◽  
Keefe B. Manning

As a medical device proves successful in adult patients, it is anticipated that a similar solution for pediatrics may be developed. However, in many cases this task has proved to be much more complex than simply scaling the device down for a miniature adult patient. Pediatric patients present a unique set of characteristics and constraints not seen in adults. These include a large range of sizes from infants to adolescents, the possible growth of the patient during use, possible anatomical deformities and a body that has not fully matured.

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R Ragusa ◽  
A Di Molfetta ◽  
S Del Turco ◽  
G Basta ◽  
M Cabiati ◽  
...  

Abstract Background Ventricular Assist Device (VAD) is increasingly used as bridge to transplantation for the treatment adult and pediatric patients with end-stage Heart Failure (HF). Unloading of heart by VAD can lead to significant molecular, structural and functional changes of cardiac muscle in HF adult patients, including an improvement of the inflammatory process. Adiponectin (ADN), an anti-inflammatory adipokine, exerts anti-hypertrophic, anti-fibrotic and anti-apoptotic effects after binding to AdipoR1, AdipoR2 and T-CAD receptors. There is an apparently paradoxical increase of ADN levels in HF adult patients, probably due ADN resistance. VAD treatment leads to an increased cardiac expression of ADN receptors in HF adults. However, little is known about the role of ADN in HF children and the effects of VAD support on ADN system in these patients. Purpose The aims of this study were to evaluate: 1) the circulating ADN levels from HF children and a control group of healthy children; 2) the effects of VAD treatment both on circulating levels of ADN and on the cardiac expression of ADN system in pediatric patients with HF. Methods Circulating levels of ADN were measured in plasma samples collected from 8 HF children [age:57±33 (mean±SD) months; 2 males; 14.2±13.5 weight; 29±8 LVEF%] before and at 4 hrs, 1, 3, 7, 14 and 30 days after VAD implant. The ADN levels of paediatric patients at baseline were compared with a group of 107 [58±7 months; 67 males] healthy children. Expression levels of AdipoR1, AdipoR2, T-CAD were determined by real-time PCR in cardiac biopsies collected from HF children at the time of VAD implant (Pre-VAD) and at the time of heart transplantation (Post-VAD). Results Circulating levels of ADN were significantly higher in HF compared to healthy children (Figure 1A). In HF children, plasma ADN decreased significantly in early post-operative time-course (up to 3 days Post-VAD implant) and returned to pre-operative levels in 1 month (Figure 1B). In cardiac biopsies, mRNA expression of AdipoR1, AdipoR2, T-CAD increased significantly after VAD treatment compared to Pre-VAD (Figure 2A–C). Conclusion In pediatric patients, high circulating levels of ADN were associated with presence of HF and were modified by VAD implant, but remained significantly abnormal. On the other hand, an increased cardiac mRNA expression of ADN receptors was observed after VAD. These results could suggest the existence of a fine tuning of the ADN system at cardiac tissue level, able to mitigate plasma abnormality and favour the cardio-protective effect of ADN. Funding Acknowledgement Type of funding source: Public grant(s) – EU funding. Main funding source(s): SensorART-A Remote Controlled Sensorized ARTificial Heart Enabling Patients Empowerment and New Therapy Approaches


ASAIO Journal ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jonathan J. Edwards ◽  
Jonathan B. Edelson ◽  
Antara Mondal ◽  
Hannah Katcoff ◽  
Nosheen Reza ◽  
...  

2004 ◽  
Vol 126 (2) ◽  
pp. 180-187 ◽  
Author(s):  
Xinwei Song ◽  
Houston G. Wood ◽  
Don Olsen

The continuous flow ventricular assist device (VAD) is a miniature centrifugal pump, fully suspended by magnetic bearings, which is being developed for implantation in humans. The CF4 model is the first actual prototype of the final design product. The overall performances of blood flow in CF4 have been simulated using computational fluid dynamics (CFD) software: CFX, which is commercially available from ANSYS Inc. The flow regions modeled in CF4 include the inlet elbow, the five-blade impeller, the clearance gap below the impeller, and the exit volute. According to different needs from patients, a wide range of flow rates and revolutions per minute (RPM) have been studied. The flow rate-pressure curves are given. The streamlines in the flow field are drawn to detect stagnation points and vortices that could lead to thrombosis. The stress is calculated in the fluid field to estimate potential hemolysis. The stress is elevated to the decreased size of the blood flow paths through the smaller pump, but is still within the safe range. The thermal study on the pump, the blood and the surrounding tissue shows the temperature rise due to magnetoelectric heat sources and thermal dissipation is insignificant. CFD simulation proved valuable to demonstrate and to improve the performance of fluid flow in the design of a small size pump.


2020 ◽  
Vol 159 (4) ◽  
pp. 1519-1527.e1 ◽  
Author(s):  
Marcus Granegger ◽  
Bente Thamsen ◽  
Thomas Schlöglhofer ◽  
Selina Lach ◽  
Andreas Escher ◽  
...  

2018 ◽  
Vol 37 (4) ◽  
pp. S65
Author(s):  
S.A. Hollander ◽  
L. Schultz ◽  
K. Dennis ◽  
A.M. Hollander ◽  
S. Rizzuto ◽  
...  

2018 ◽  
Vol 37 (4) ◽  
pp. S405-S406
Author(s):  
K. Puri ◽  
A. Jimenez Gomez ◽  
I. Adachi ◽  
S.W. Denfield ◽  
A.G. Cabrera ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document